NDA 020524 · Pharmobedient
Mentax
Butenafine Hydrochloride · Topical
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 17, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Oct 18, 1996
Approved uses
3
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 6, 2001 Supplement 5 · Efficacy ReviewLetterLabel
- Nov 25, 1997 Supplement 1 · Efficacy
- Oct 18, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- MENTAX · BUTENAFINE HYDROCHLORIDE 1% · CREAM, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Butenafine" as an intervention, any sponsor and status, largest first.
- Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01580878 · 707 participants · Start Jan 2012 · Primary completion Aug 2012
Drug: Butenafine Hydrochloride Cream, 1%; Lotrimin Ultra® and 1 more · For: Tinea Pedis
- Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT00835510 · 548 participants · Start Jun 2008 · Primary completion Oct 2008
Drug: Butenafine cream 1% manufactured by Taro; Lotrimin Ultra (butenafine) 1% and 1 more · For: Tinea Pedis
Sites: Burbank, California; San Diego, California; Miami, Florida · 17 sites in all
- Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea PedisPivotal-lookingTerminated
Sun Pharmaceutical Industries, Inc.Industry
NCT01119742 · 428 participants · Start Jul 2010 · Primary completion Mar 2011
Drug: Butenafine Hydrochloride 1%; Butenafine Hydrochloride 1% B and 3 more · For: Interdigital Tinea Pedis
- Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04531540 · 225 participants · Start Sep 9, 2013 · Primary completion Oct 18, 2013
Drug: Butenafine HCl 1% (BAY1896425) · For: Hypersensitivity
Sites: Fairfield, New Jersey
- Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy ParticipantsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04532164 · 137 participants · Start Jun 10, 2013 · Primary completion Nov 11, 2013
Drug: Butenafine HCl 1% (BAY1896425) - Induction Phase; Butenafine HCl 1% (BAY1896425) - Challenge Phase · For: Dermatitis, Photoallergic
Sites: Fairfield, New Jersey
United LaboratoriesIndustry
NCT03999437 · 42 participants (planned) · Start Jan 2, 2019 · Primary completion Dec 13, 2019
Drug: TERBINAFINE HYDROCHLORIDE (1%); BUTENAFINE HYDROCHLORIDE (1%) and 1 more · For: Tinea Pedis
Sites: City of Muntinlupa, Philippines
- Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human SubjectsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04531527 · 32 participants · Start Jun 24, 2013 · Primary completion Jun 28, 2013
Drug: Butenafine HCl 1% (BAY1896425) · For: Dermatitis, Phototoxic
Sites: Fairfield, New Jersey
- Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04531813 · 32 participants · Start Jun 10, 2013 · Primary completion Jul 1, 2013
Drug: Butenafine HCl 1% (BAY1896425); Positive Control-Sodium lauryl sulfate (SLS) · For: Hypersensitivity
Sites: Fairfield, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2014 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2011 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2008 · Systematic Review
- The antifungal agent butenafine manifests anti-inflammatory activity in vivo.
Nahm WK, Orengo I, Rosen T · J Am Acad Dermatol 1999 · Clinical Trial, Randomized Controlled Trial
- Are placebo-controlled trials of creams for athlete's foot still justified?
Crawford F, Harris R, Williams HC · Br J Dermatol 2008 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent.
Greer DL, Weiss J, Rodriguez DA, et al. · J Am Acad Dermatol 1997 · Clinical Trial, Multicenter Study
Sponsor: Pharmobedient
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.